Phase II Trial of Afatinib in Elderly Patients Aged Over 75 Years with EGFR Mutation Positive Non-Small Cell Lung Cancer

被引：1
|
作者：
Ko, R. [1 ]
Oizumi, S. [2 ]
Mizugaki, H. [3 ]
Fujita, Y. [2 ]
Harada, T. [4 ]
Takashina, T. [5 ]
Igawa, S. [6 ]
Watanabe, K. [7 ]
Hotta, T. [8 ]
Minemura, H. [9 ]
Saeki, S. [10 ]
Yagishita, S. [11 ]
Hamada, A. [11 ]
机构：
[1] Juntendo Univ, Grad Sch Med, Resp Med, Tokyo, Japan
[2] Natl Hosp Org Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[3] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[4] Jcho Hokkaido Hosp, Dept Resp Med, Sapporo, Hokkaido, Japan
[5] Iwamizawa Municipal Gen Hosp, Iwamizawa, Japan
[6] Kitasato Univ, Sch Med, Resp Med, Sagamihara, Kanagawa, Japan
[7] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[8] Shimane Univ, Fac Med, Izumo, Shimane, Japan
[9] Fukushima Med Univ, Pulm Med, Fukushima, Japan
[10] Kumamoto Univ, Kumamoto, Japan
[11] Natl Canc Ctr, Res Inst, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Afatinib; Adverse events; Elderly patients;
D O I：
10.1016/j.jtho.2019.08.1187
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.14-36
引用
收藏
页码：S568 / S568
页数：1
相关论文
共 50 条
  • [31] Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib
    Liao, Bin-Chi
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    CURRENT ONCOLOGY REPORTS, 2017, 19 (01)
  • [32] Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib
    Bin-Chi Liao
    Chia-Chi Lin
    James Chih-Hsin Yang
    Current Oncology Reports, 2017, 19
  • [33] The safety of afatinib for the treatment of non-small cell lung cancer
    Barron, Feliciano
    de la Torre-Vallejo, Martha
    Luz Luna-Palencia, Rosa
    Cardona, Andres F.
    Arrieta, Oscar
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (11) : 1563 - 1572
  • [34] Afatinib in EGFR TKI-naive patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study
    Marinis, Filippo de
    Laktionov, Konstantin K.
    Poltoratskiy, Artem
    Egorova, Inna
    Hochmair, Maximilian
    Passaro, Antonio
    Migliorino, Maria Rita
    Metro, Giulio
    Gottfried, Maya
    Tsoi, Daphne
    Ostoros, Gyula
    Rizzato, Simona
    Mukhametshina, Guzel Z.
    Schumacher, Michael
    Novello, Silvia
    Dziadziuszko, Rafal
    Tang, Wenbo
    Clementi, Laura
    Cseh, Agnieszka
    Kowalski, Dariusz
    LUNG CANCER, 2021, 152 : 127 - 134
  • [35] Phase I Study of Afatinib Plus Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
    Tokito, T.
    Ko, R.
    Imamura, C.
    Shukuya, T.
    Shimada, N.
    Koyama, R.
    Yamada, K.
    Ishii, H.
    Azuma, K.
    Takahashi, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S565 - S565
  • [36] Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
    Hochmair, Maximilian J.
    Morabito, Alessandro
    Hao, Desiree
    Yang, Cheng-Ta
    Soo, Ross A.
    Yang, James C-H
    Gucalp, Rasim
    Halmos, Balazs
    Wang, Lara
    Golembesky, Amanda
    Maerten, Angela
    Cufer, Tanja
    FUTURE ONCOLOGY, 2018, 14 (27) : 2861 - 2874
  • [37] First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial
    Aix, Santiago Ponce
    Park, Keunchil
    Tan, Eng-Huat
    O'Byrne, Kenneth
    Zhang, Li
    Boyer, Michael
    Mok, Tony
    Hirsh, Vera
    Yang, James Chih-Hsin
    Maerten, Angela
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S203 - S204
  • [38] A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Igawa, Satoshi
    Kasajima, Masashi
    Ono, Taihei
    Ozawa, Takahiro
    Kakegawa, Mikiko
    Kusuhara, Seiichiro
    Sato, Takashi
    Nakahara, Yoshiro
    Fukui, Tomoya
    Yokoba, Masanori
    Kubota, Masaru
    Mitsufuji, Hisashi
    Sasaki, Jiichiro
    Naoki, Katsuhiko
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 8695 - 8705
  • [39] Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)
    Araki, Taisuke
    Kanda, Shintaro
    Komatsu, Masamichi
    Sonehara, Kei
    Tateishi, Kazunari
    Takada, Munetake
    Kato, Akane
    Yamamoto, Manabu
    Nishie, Kenichi
    Hama, Mineyuki
    Agatsuma, Toshihiko
    Kakizaki, Yumiko
    Yoshiike, Fumiaki
    Matsuo, Akemi
    Chiaki, Tomoshige
    Samizo, Kanae
    Takagi, Yoshiko
    Yamaura, Maki
    Hanaoka, Masayuki
    Koizumi, Tomonobu
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (06) : 1320 - 1327
  • [40] Afatinib for the treatment of non-small cell lung cancer
    Biello, Federica
    Maggioni, Claudia
    Rijavec, Erika
    Genova, Carlo
    Barletta, Giulia
    Gualco, Elisa
    Truini, Anna
    Coco, Simona
    Dal Bello, Maria Giovanna
    Vanni, Irene
    Alama, Angela
    Boccardo, Francesco
    Grossi, Francesco
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (11): : 1357 - 1364
12345